Filter posts

R&D – Slow Growth Continues

According to a new report from EvaluatePharma, global pharmaceutical R&D had negative growth in 2012 …

Industry Growth Factor: Biologics

Last week, EvaluatePharma released their updated sales and R&D outlook for the drug industry in their …

Only 12% of Public Biotechs are Profitable

Of the 286 biotech companies trading on public exchanges today, 241 focus on drug development, …

Breakthrough Designations Reach 13

One of the outcomes of the 2012 Food and Drug Administration Safety and Innovation Act …

Results from the BIO Convention 2013 Meeting Analysis of Therapeutic In/Out Licensors

BIO’s results from the BIO 2013 Convention 1×1 meeting analysis conducted to identify trends and intentions …

BIO-Europe Spring Opening Remarks

BIO’s own David Thomas, Director of Industry Research, delivered opening remarks at the BIO-Europe Spring …

A Bright Future for Orphan Disease Indications

In celebration of National Rare Disease Day BIO’s Industry Analysis team took a look at recently-approved …

The IPO Road Less Traveled: Form 10

When investors talk about alternate exits for private companies beyond the traditional IPO they are …

Putting a Ring on It: Advice on Successful Drug Development Collaborations

Drug development partnerships can look lucrative to small biotechs eager to monetize their discoveries, but, …

Biobuck M&A in Full Gear

The 2012 M&A results are in and trends are mixed. Last year was a down …